Infections in Kidney Transplantation

A special issue of Medicina (ISSN 1648-9144).

Deadline for manuscript submissions: closed (31 August 2019) | Viewed by 2917

Special Issue Editor


E-Mail Website
Guest Editor
Monash University, Department of Infectious Diseases, Melbourne, Australia
Interests: fungal infections; immune function; Aspergillus virulence; resistance and host immune responses; Mycobacterium abscessus in transplant recipients

Special Issue Information

Dear Colleagues,

Kidney transplantation remains as the treatment of choice for many patients with end-stage kidney disease. Patient and graft survival have improved, mainly due to advances in immunosuppression regimens and antimicrobial prophylaxis.However, infection is the second most common cause of death with a functioning graft in renal transplant recipients (RTRs). Thus, prevention as well as early diagnosis and management are critical to improving patient and graft survival. Donor and recipient screening are essential to optimize both pre- and post-transplant preventative strategies, including vaccination. Improved diagnostics tools and their increased application in routine care now allow for specific microbiological diagnoses to better target therapy. The increasing availability of directly acting anti-viral (DAA) agents for hepatitis C treatment is allowing for the expansion of the donor pool and increasing recipient eligibility. Increasing Gram-negative resistance remains a challenge, particularly for urinary tract infections in RTRs. The role of the microbiome and individualized care are being increasingly recognized. In this Issue, we will provide an update on the prevention, diagnosis, and management of common infections in RTRs and provide some insights into future directions and emerging trends in the area of infections in RTRs.

Dr. Orla Morrissey
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • kidney transplantation
  • prophylaxis
  • hepatitis C
  • cytomegalovirus
  • BK virus
  • Enterobacteriaceae
  • resistance
  • fungus
  • pneumocystis
  • microbiome
  • whole-genome sequencing

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

17 pages, 374 KiB  
Review
Infectious Complications Following Kidney Transplantation—A Focus on Hepatitis C Infection, Cytomegalovirus Infection and Novel Developments in the Gut Microbiota
by Samuel Chan, Nicole M Isbel, Carmel M Hawley, Scott B Campbell, Katrina L Campbell, Mark Morrison, Ross S Francis, E Geoffrey Playford and David W Johnson
Medicina 2019, 55(10), 672; https://doi.org/10.3390/medicina55100672 - 4 Oct 2019
Cited by 8 | Viewed by 2716
Abstract
The incidence of infectious complications, compared with the general population and the pre-transplant status of the recipient, increases substantially following kidney transplantation, causing significant morbidity and mortality. The potent immunosuppressive therapy given to prevent graft rejection in kidney transplant recipients results in an [...] Read more.
The incidence of infectious complications, compared with the general population and the pre-transplant status of the recipient, increases substantially following kidney transplantation, causing significant morbidity and mortality. The potent immunosuppressive therapy given to prevent graft rejection in kidney transplant recipients results in an increased susceptibility to a wide range of opportunistic infections including bacterial, viral and fungal infections. Over the last five years, several advances have occurred that may have changed the burden of infectious complications in kidney transplant recipients. Due to the availability of direct-acting antivirals to manage donor-derived hepatitis C infection, this has opened the way for donors with hepatitis C infection to be considered in the donation process. In addition, there have been the development of medications targeting the growing burden of resistant cytomegalovirus, as well as the discovery of the potentially important role of the gastrointestinal microbiota in the pathogenesis of post-transplant infection. In this narrative review, we will discuss these three advances and their potential implications for clinical practice. Full article
(This article belongs to the Special Issue Infections in Kidney Transplantation)
Back to TopTop